Sphingosylphosphorylcholine potentiates vasoreactivity and voltage-gated Ca2+ entry via NOX1 and reactive oxygen species

• Published in: Cardiovascular research Vol. 106; no. 1; pp. 121 - 130
• Main Authors: Shaifta, Yasin, Snetkov, Vladimir A, Prieto-Lloret, Jesus, Knock, Greg A, Smirnov, Sergey V, Aaronson, Philip I, Ward, Jeremy P T
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.04.2015
• Subjects: Animals; Calcium Channels - drug effects; Calcium Channels - physiology; Cyclic N-Oxides - pharmacology; Dose-Response Relationship, Drug; Membrane Glycoproteins - deficiency; Membrane Glycoproteins - genetics; Membrane Glycoproteins - physiology; Mesenteric Arteries - drug effects; Mesenteric Arteries - physiology; Mice; Mice, Knockout; Models, Animal; NADH, NADPH Oxidoreductases - physiology; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidases - deficiency; NADPH Oxidases - genetics; NADPH Oxidases - pharmacology; NADPH Oxidases - physiology; Original; Phosphorylcholine - analogs & derivatives; Phosphorylcholine - pharmacology; Protein Kinase C-epsilon - pharmacology; Pulmonary Artery - drug effects; Pulmonary Artery - physiology; Reactive Oxygen Species - metabolism; Signal Transduction - drug effects; Signal Transduction - physiology; Sphingosine - analogs & derivatives; Sphingosine - pharmacology; Spin Labels; Type C Phospholipases - pharmacology; Vasoconstriction - drug effects; Vasoconstriction - physiology; Reactive oxygen species; Vascular smooth muscle; NADPH oxidase; Protein kinase C epsilon; L-type Ca2+ channels

Sphingosylphosphorylcholine (SPC) elicits vasoconstriction at micromolar concentrations. At lower concentrations (≤1 µmol/L), however, it does not constrict intrapulmonary arteries (IPAs), but strongly potentiates vasoreactivity. Our aim was to determine whether this also occurs in a systemic artery...